β-Thalassemia: HBB (Known Mutation)
Use
The β-Thalassemia: HBB (Known Mutation) test is utilized to detect the presence or absence of familial mutations in individuals who may be carriers or affected by β-thalassemia. It is specifically used when the mutation in question is known and can be documented by the ordering physician. This genetic test aids in the diagnosis and management of β-thalassemia, assisting clinicians in making informed decisions about patient care, particularly in family testing scenarios where a known mutation exists.
Special Instructions
This test option should be selected when the mutation is known and clearly documented by the healthcare provider. A detailed submission including an attestation of informed consent from the patient is a requirement. Furthermore, in cases involving family tests, results from the index case are needed if they were not initially processed at a LabCorp facility.
Limitations
The assay has limitations including its inability to reliably detect mosaic variants, deep intronic variants, large deletions, duplications, inversions, or other structurally complex genomic alterations. Its accuracy can be compromised by factors such as homopolymer repeats and allele-dropout due to sequence polymorphisms at primer binding sites. The test is unable to determine whether two heterozygous variants are located on the same or different chromosomes.
Methodology
NGS
Biomarkers
LOINC Codes
- 21689-5
- 21689-5
Result Turnaround Time
21-28 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
2 mL
Minimum Volume
2 mL
Container
Lavender-top (EDTA) tube
Collection Instructions
Ship overnight at room temperature.
Causes for Rejection
Frozen specimen; hemolysis; quantity not sufficient for analysis; improper container
